CD184 Antibody (YA4664)

CD184 Antibody (YA4664) is a non-conjugated antibody, targeting to CD184.

P61073

7852 [NCBI]

Shipping with blue ice.

Function：Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation (PubMed:10452968, PubMed:18799424, PubMed:24912431, PubMed:28978524). Involved in the AKT signaling cascade (PubMed:24912431). Plays a role in regulation of cell migration, e.g. during wound healing (PubMed:28978524). Acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels (PubMed:20228059). Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Involved in hematopoiesis and in cardiac ventricular septum formation. Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. Involved in cerebellar development. In the CNS, could mediate hippocampal-neuron survival (By similarity); (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) for human immunodeficiency virus-1/HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus (PubMed:10074122, PubMed:10756055, PubMed:8849450, PubMed:8929542, PubMed:9427609)

Subcellular Localization：Cell membrane; Multi-pass membrane protein; Cell junction; Early endosome; Late endosome; Lysosome

Expression：
Tissue_specificity:This protein is expressed in a variety of tissues, including peripheral blood leukocytes, spleen, thymus, spinal cord, heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex and medulla oblongata (including microglia and astrocytes) , cerebral microvessels, coronary arteries, and umbilical cord endothelial cells. Isoform 1 was dominant in all tissues examined.

Induction: (Microbial infection) May be down-regulated by Human cytomegalovirus/HHV-5; (Microbial infection) May be down-regulated by HIV-1 tat

Isoforms & Post-Translational Modification：P61073 has 2 isomers: P61073-1: 39746 Da (predicted); P61073-2: 40221 Da (predicted).
Phosphorylated on agonist stimulation. Rapidly phosphorylated on serine and threonine residues in the C-terminal. Phosphorylation at Ser-324 and Ser-325 leads to recruitment of ITCH, ubiquitination and protein degradation;Ubiquitinated after ligand binding, leading to its degradation (PubMed:28978524). Ubiquitinated by ITCH at the cell membrane on agonist stimulation (PubMed:14602072, PubMed:34927784). The ubiquitin-dependent mechanism, endosomal sorting complex required for transport (ESCRT), then targets CXCR4 for lysosomal degradation. This process is dependent also on prior Ser-/Thr-phosphorylation in the C-terminal of CXCR4. Also binding of ARRB1 to STAM negatively regulates CXCR4 sorting to lysosomes though modulating ubiquitination of SFR5S;Sulfation on Tyr-21 is required for efficient binding of CXCL12/SDF-1alpha and promotes its dimerization. Tyr-7 and Tyr-12 are sulfated in a sequential manner after Tyr-21 is almost fully sulfated, with the binding affinity for CXCL12/SDF-1alpha increasing with the number of sulfotyrosines present. Sulfotyrosines Tyr-7 and Tyr-12 occupy clefts on opposing CXCL12 subunits, thus bridging the CXCL12 dimer interface and promoting CXCL12 dimerization;O- and N-glycosylated. Asn-11 is the principal site of N-glycosylation. There appears to be very little or no glycosylation on Asn-176. N-glycosylation masks coreceptor function in both X4 and R5 laboratory-adapted and primary HIV-1 strains through inhibiting interaction with their Env glycoproteins. The O-glycosylation chondroitin sulfate attachment does not affect interaction with CXCL12/SDF-1alpha nor its coreceptor activity

Subunit：Monomer. Can form homodimers (PubMed:20929726). Interacts with CD164 (PubMed:17077324). Interacts with ARRB2; the interaction is dependent on the C-terminal phosphorylation of CXCR4 and allows activation of MAPK1 and MAPK3. Interacts with ARR3; the interaction is dependent on the C-terminal phosphorylation of CXCR4 and modulates calcium mobilization (PubMed:20048153). Interacts with RNF113A; the interaction, enhanced by CXCL12, promotes CXCR4 ubiquitination and subsequent degradation (PubMed:28978524). Interacts (via the cytoplasmic C-terminal) with ITCH (via the WW domains I and II); the interaction, enhanced by CXCL12, promotes CXCR4 ubiquitination and leads to its degradation. Interacts with extracellular ubiquitin. Interacts with DBN1; this interaction is enhanced by antigenic stimulation. Following LPS binding, may form a complex with GDF5, HSP90AA1 and HSPA8

CXCR4; FB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; LAP-3; LESTR; NPY3R; NPYRL; WHIMS; HSY3RR; NPYY3R; WHIMS1; D2S201E; C-X-C chemokine receptor type 4 antibody; CD184 antibody; CD184 antigen antibody; Chemokine; C X C motif; receptor 4 antibody; Chemokine CXC Motif Receptor 4 antibody; CXC-R4 antibody; CXCR-4 antibody; CXCR4 antibody; CXCR4_HUMAN antibody; D2S201E antibody; FB22 antibody; Fusin antibody; HM89 antibody; HSY3RR antibody; LAP 3 antibody; LAP3 antibody; LCR1 antibody; LESTR antibody; Leukocyte derived seven transmembrane domain receptor antibody; Leukocyte-derived seven transmembrane domain receptor antibody; Lipopolysaccharide associated protein 3 antibody; Neuropeptide Y receptor Y3 antibody; NPY3R antibody; NPYR antibody; NPYRL antibody; NPYY3 antibody; NPYY3R antibody; Probable G protein coupled receptor lcr1 homolog antibody; SDF 1 receptor antibody; SDF-1 receptor antibody; SEVEN-TRANSMEMBRANE-SEGMENT RECEPTOR antibody; Stromal cell derived factor 1 receptor antibody; Stromal cell-derived factor 1 receptor antibody; WHIM antibody; WHIMS antibody;